Sonothrombolysis in Patients With STEMI

• Status: Completed
• Trial end date: 2019-10-03
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates what effect sonothrombolysis may have on spontaneous reperfusion, microvascular obstruction, left ventricular function and infarct size in patients presenting with their first ST-segment Elevation Myocardial Infarction.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Harald Becher
• Collaborators: Alberta Health Services; University of Alberta

Criteria

Inclusion Criteria:

Patients presenting with STEMI within 6 hours of symptom onset and:

1. Are expected to receive reperfusion therapy with primary PCI

2. Have a high-risk STEMI ECG defined as:

• ≥2mm ST-segment elevation in 2 anterior or lateral leads; or

• ≥2 mm ST-segment elevation in 2 inferior leads coupled with ST segment depression in 2 contiguous anterior leads for a total ST-segment deviation of ≥4mm

3. Age ≥30 years.

4. Adequate apical and/or parasternal images by echocardiography

Exclusion Criteria:

1. Isolated inferior STEMI without anterior ST-segment depression

2. Previous coronary bypass surgery

3. Cardiogenic shock

4. Known or suspected hypersensitivity to ultrasound contrast agent used for the study

5. Life expectancy of less than two months or terminally ill.

6. Known bleeding diathesis or contraindication to glycoprotein 2b/3a inhibitors, anticoagulants, or aspirin

7. Known large right to left intracardiac shunts.